JAK1 and COVID-19: Targeting the JAK1 enzyme and decreases the activity of the immune system, reduce the expression of T-helper 2 and 22 cytokines and also the levels of interleukin6 (IL-6) like ruxolitinib that inhibits damage lung in patients with COVID-19.